Treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy
Marius Erik Mayerhöfer
Psycho-oncology: measuring levels of emotional distress in cancer patients and their families
Using mouse models to develop drugs targeting resistance mechanisms in melanoma
The success of the dabrafenib and trametinib combination in BRAF-mutated melanoma
What support can doctors provide patients in terms of pyschological well-being?
Melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better PFS
Blocking C-MET and BRAF pathways in melanoma to overcome resistance in mouse models